<DOC>
	<DOCNO>NCT00604630</DOCNO>
	<brief_summary>The purpose randomize , double-blind , placebo-controlled multicenter study determine cohort 506 patient acute ischemic stroke middle cerebral artery territory , effect three-day high-dose , intravenous erythropoietin treatment functional outcome follow-up 90 day .</brief_summary>
	<brief_title>Multicenter Efficacy Study Recombinant Human Erythropoietin Acute Ischemic Stroke</brief_title>
	<detailed_description />
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Infarction , Middle Cerebral Artery</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Ischemic stroke middle cerebral artery territory Clearly define time onset Confirmed MRI ( DWI , Flair ) NIH Stroke Scale ≥ 5 Age &gt; 18 year Treatment within 6h onset symptom Informed consent patient , relatives independent physician Life expectancy &gt; 90 day Coma precoma ( level consciousness ≥ 2 NIH Stroke Scale ) Previous stroke within territory Intracranial subarachnoidal hemorrhage Traumatic brain injury brain operation within last 4 week Neoplasia , septic embolism , infectious endocarditis MRI contraindication Renal failure ( i.e . dependent dialysis ) Known malignant/lifethreatening disease Known myeloproliferative disorder , polycythemia Known allergy antibody erythropoietin Participation intervention trial Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2008</verification_date>
	<keyword>stroke</keyword>
	<keyword>EPO</keyword>
	<keyword>erythropoietin</keyword>
	<keyword>ischemia</keyword>
	<keyword>hypoxia</keyword>
	<keyword>antiapoptosis</keyword>
	<keyword>neuroprotection</keyword>
	<keyword>rtPA</keyword>
	<keyword>thrombolysis</keyword>
	<keyword>stroke , middle cerebral artery</keyword>
	<keyword>Ischemic stroke middle cerebral artery territory</keyword>
</DOC>